This is one of the most exciting periods for pharma in Japan, both in terms of opportunities for domestic and international companies. This past year has been transformative for Japanese pharma, with many experts foreseeing stronger growth in the medium term.


Gathering 20,000+ pharma professionals and hosting 550+ exhibitors from ingredients, contract services and biopharma through to technology, packaging and machinery, CPhI Japan is the ideal business platform for international pharma professionals to join in order to grow business in the rapidly changing Japanese pharmaceutical market. In addition to domestic exhibiting companies, there are new international ingredients suppliers, CDMOs, natural ingredients, machinery, biopharma and generic companies.


CPhI Japan hosts a wide range of free and paid seminars and conferences from the government, industry associations and other key players. The agenda features a blend of formats and covers everything from commercial challenges to legal changes and technical workshops.


What our visitors say:


“A major event in Asia where the pharmaceutical world gets together for major discussions, networking and business prospects. A unique opportunity for us to meet with Japanese pharma companies.” - Waldo Mossi, Helsinn Advanced Synthesis


"Attending CPhI Japan was a good chance to get in contact with Japanese companies and to understand the Japanese pharma industry and trends." - Andrea Salvadori, Sales Area Manager, PQE


Find out more about the event: www.cphi.com

To register click here.

Go to article: Home | The Scottish Uprising Go to article: In this issueGo to article: NSFGo to article: ContentsGo to article: Daiichi JitsugyoGo to article: NewsGo to article: Hapa Company InsightGo to article: BioadviceGo to article: The pharma industry briefingGo to article: Komtur Pharmaceuticals Company InsightGo to article: Komtur PharmaceuticalsGo to article: Where is the UK’s supply of Migraleve?Go to article: AtoZ-CRO GmbH Company InsightGo to article: AtoZ-CRO GmbHGo to article: Drugs from corn? Harvesting Mirexus’ phytoglycogen nano-particleGo to article: Phoenix Group Company InsightGo to article: Phoenix Group Go to article: Castleman disease: does machine learning hold the key to better treatment?Go to article: Capsugel Company InsightGo to article: CalleryGo to article: A health check for Scotland’s pharmaceutical industry Go to article: ImmuMap Company Insight Go to article: ImmuMapGo to article: Moderna’s gamble: what’s behind biotech’s biggest-ever IPO?Go to article: Centaur Clinical | Company InsightGo to article: Centaur ClinicalGo to article: DelSiTech: leveraging silica’s properties to improve drug deliveryGo to article: Alpex Pharma Go to article: AlbypharmaGo to article: ‘Gene genie’: can CRISPR/Cas9 deliver on its promise to transform genome therapy?Go to article: ZenatekGo to article: EventsGo to article: SanofiGo to article: Event: CPhl JapanGo to article: PfanstiehlGo to article: Next issue